|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESEARCH |
M Nagaya, Islet Transplantation and Cell Biology , Joslin Diabetes Center , Boston, 02215 , United States
H Katsuta, Islet Transplantation and Cell Biology, Joslin Diabetes Center, Boston, United States
H Kaneto, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka, Japan
S Bonner-Weir, Islet Transplantation and Cell Biology, Joslin Diabetes Center, Boston, United States
G Weir, Boston, United States
Correspondence: Masaki Nagaya, Email: Masaki.Nagaya{at}joslin.harvard.edu
Abstract
Transdifferentiation of cells from a patient's own liver into pancreatic β-cells could be useful for β-cell replacement. We hypothesized that intrahepatic biliary epithelial cells (IHBECs) could become a new source of insulin-producing cells.
IHBECs isolated from adult mice were expanded using our novel culture method, termed collagen-embedded floating culture method (CEFCM). With CEFCM, IHBECs formed three-dimensional ductal cysts and rapidly expanded their number about 15-fold within 2 wk. Over 90% of cells were positive for cytokeratin 7 and 19. At day14, IHBECs were transfected with adenoviral (Ad)- pancreas duodenum homeobox 1 (Pdx-1), NeuroD, or Pdx-1/VP16. After 7 additional days in serum- and insulin-free differentiation medium (DM), cell phenotypes were determined by RT-PCR, immunostaining and ELISA for insulin.
In DM Control IHBECs started to express some endocrine progenitor genes (Neurogenin3, NeuroD, Nkx6.1 and Pdx-1) but lacked Insulin mRNA. Transduced expression of Pdx-1, NeuroD or Pdx-1/VP16 led to expression of not only Insulin but also GLUT2 and Prohormone convertase 1 and 2. About 3% of 4000 cells counted in Pdx-1/VP16 transduced cultures stained strongly for C-peptide suggesting that a subpopulation may have the capacity for differentiation. Transduced cells released insulin (Ad-Pdx-1 0.08±0.05, Ad-NeuroD 0.33±0.09, Ad-Pdx-1/VP16 0.37±0.14 ng/1X105 cells after 48h in culture).
IHBECs can be markedly expanded, and then with molecular manipulation a subpopulation of these cells can differentiate towards a β-cell phenotype. This approach may lead to a new source of β-cells that can be used for transplantation in diabetes.
This article has been cited by other articles:
![]() |
S. Sahu, D. Tosh, and A. A Hardikar New sources of {beta}-cells for treating diabetes J. Endocrinol., July 1, 2009; 202(1): 13 - 16. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH |